 |
 |

Reliability of Counting Actinic Keratoses Before and After Brief Consensus Discussion
The VA Topical Tretinoin Chemoprevention (VATTC) Trial
Martin A. Weinstock, MD, PhD;
Stephen F. Bingham, PhD;
Gary W. Cole, MD;
David Eilers, MD;
Mark F. Naylor, MD;
James Kalivas, MD;
J. Richard Taylor, MD;
Hayes B. Gladstone, MD;
Daniel J. Piacquadio, MD;
John J. DiGiovanna, MD
Arch Dermatol. 2001;137:1055-1058.
Objective To assess the reliability of counts of actinic keratoses (AKs) and the effect of a brief joint discussion of discrepancies on that reliability.
Design and Intervention Seven dermatologists independently counted AKs on the face and ears before and after a brief joint discussion of discrepancies.
Setting and Patients A volunteer sample of 9 patients from the ongoing VA (Department of Veterans Affairs) Topical Tretinoin Chemoprevention (VATTC) Trial. All participating individuals are veterans and have had 2 or more keratinocyte carcinomas (basal or squamous cell carcinoma) in the 5 years before enrollment in the study.
Main Outcome Measure Standard deviation of estimates of the Poisson regression parameter for the dermatologists.
Results Substantial variation was found among the dermatologists in their AK counts. The SD of the parameter estimates for the dermatologists decreased from 0.45 to 0.24 after the brief joint discussion, a 47% decrease (P = .076). The variation attributable to the dermatologists also decreased substantially ( 26 decrease, 94 to 12).
Conclusions Actinic keratoses are common, and there is a continuous spectrum of lesions that ranges from sun-damaged skin to squamous cell carcinoma in situ. Clinical distinguishing features may be difficult to delineate precisely. Counts of AK are commonly performed, but appear to be unreliable, even when performed by experienced dermatologists. Joint discussion of discrepancies may enhance the reliability of these counts, although substantial variation remains. Research that relied on these counts must be reevaluated in light of the marked variation among expert observers. Future studies should consider measures to assess and enhance reliability.
From the Dermatoepidemiology Unit, Veterans Affairs (VA) Medical Center, Providence (Dr Weinstock), and Department of Dermatology, Rhode Island Hospital and Brown University, Providence (Drs Weinstock and DiGiovanna); the VA Cooperative Studies Program Coordinating Center, Perry Point, Md (Dr Bingham); Department of Dermatology, VA Medical Center Long Beach, Long Beach, Calif (Dr Cole); Department of Dermatology, University of CaliforniaIrvine (Dr Cole); Division of Dermatology, Hines VA Medical Center, Hines, Ill (Dr Eilers); Division of Dermatology, Loyola University, Chicago, Ill (Dr Eilers); Department of Dermatology, VA Medical Center Oklahoma City and University of Oklahoma, Oklahoma City (Dr Naylor); Department of Dermatology, Carl T. Hayden VA Medical Center and University of Arizona, Phoenix (Dr Kalivas); Department of Dermatology, University of Miami, and Dermatology Service, Miami VA Medical Center, Miami, Fla (Dr Taylor); Department of Dermatology, VA Medical Center West Los Angeles, Los Angeles, Calif (Dr Gladstone); and Department of Dermatology, University of CaliforniaSan Diego (Dr Piacquadio). Dr Gladstone is now affiliated with the Division of Dermatologic Surgery, Stanford University, Stanford, Calif.
RELATED ARTICLE
Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2001;137(8):1122-1123.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Clinical Recognition of Actinic Keratoses in a High-Risk Population: How Good Are We?
Venna et al.
Arch Dermatol 2005;141:507-509.
ABSTRACT
| FULL TEXT
|